ConKay Medical Systems — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ConKay Medical Systems is a private, early-stage medical device innovator targeting the significant unmet need of valvular regurgitation within the heart failure population. Founded in 2019, the company has gained recognition through programs like MedTech Innovator and UCSF Rosenman Innovator, indicating validation of its potential. Operating in the pre-revenue stage, ConKay is actively fundraising for its Series A round to advance its technology pipeline. The company's vision centers on creating impactful cardiovascular technologies to improve patient outcomes.

CardiovascularHeart Failure

Technology Platform

Medical device platform for the minimally invasive (likely transcatheter) treatment of valvular regurgitation.

Opportunities

The company is targeting a large and growing market for transcatheter solutions to valvular heart disease, particularly in the underserved heart failure population.

Recognition from MedTech Innovator and UCSF Rosenman provides third-party validation and networking opportunities to attract investors and partners.

Risk Factors

As a pre-revenue, early-stage company, ConKay faces high technical and clinical development risk, intense competition from large medtech players, and total dependence on securing Series A and future financing to continue operations.

Competitive Landscape

The transcatheter valve repair market is dominated by established giants like Abbott (MitraClip, TriClip) and Edwards Lifesciences. Competition is fierce, requiring new entrants to demonstrate clear clinical or usability advantages. The tricuspid valve space is less crowded but attracting significant investment.

More companies in Digital Health & Biotech SaaS →More companies in United States →